Search Results - "Köse, Fatih"

Baytarnâmeler bağlamında at-atçılık ve at hastalıkları: Fatih Köse by Köse, Fatih

Get more information

Treatment outcomes of early stage endometrial cancer patients: single center experience by Sedef,Ali Murat, Karaduman,Didem, Besen,Ali Ayberk, Mertsoylu,Hüseyin, Köse,Fatih

“…Purpose: The aim of this study was to evaluate clinicopathological characteristics and treatment outcomes of early stages endometrial cancer patients in our…”
Get full text

Clinicohistopathological features and treatment outcomes of neuroendocrine tumors: a single center experience by Özyılkan,Özgür, Sedef,Ali Murat, Köse,Fatih, Sümbül,Ahmet Taner, Mertsoylu,Hüseyin, Besen,Ali Ayberk, Sezer,Ahmet, Abalı,Hüseyin

“…Purpose: Tumor and patient characteristics of neuroendocrine tumors (NET) significantly change between geographical locations that probably induced by…”
Get full text

Unexpected skin lesions after axitinib treatment by Sedef, Ali Murat, Köse, Fatih, Rişvanoğlu, Elvan Endoğru, Sumbul, Ahmet Taner, Ulaş, Melda, Bal, Nebil, Özyılkan, Özgür

Get full text

Osmanlı Devleti'nde Nevruz: Fatih Köse by Köse, Fatih

Get more information

Tisotumab Vedotin in Combination With Carboplatin, Pembrolizumab, or Bevacizumab in Recurrent or Metastatic Cervical Cancer: Results From the innovaTV 205/GOG-3024/ENGOT-cx8 Study by Vergote, Ignace, Van Nieuwenhuysen, Els, O'Cearbhaill, Roisin E, Westermann, Anneke, Lorusso, Domenica, Ghamande, Sharad, Collins, Dearbhaile C, Banerjee, Susana, Mathews, Cara A, Gennigens, Christine, Cibula, David, Tewari, Krishnansu S, Madsen, Kristine, Köse, Fatih, Jackson, Amanda L, Boere, Ingrid A, Scambia, Giovanni, Randall, Leslie M, Sadozye, Azmat, Baurain, Jean-François, Gort, Eelke, Zikán, Michal, Denys, Hannelore G, Ottevanger, Nelleke, Forget, Frédéric, Mondrup Andreassen, Camilla, Eaton, Lamar, Chisamore, Michael J, Viana Nicacio, Leonardo, Soumaoro, Ibrahima, Monk, Bradley J

“…Tissue factor is highly expressed in cervical carcinoma and can be targeted by tisotumab vedotin (TV), an antibody-drug conjugate. This phase Ib/II study…”
Get full text

A randomized, open-label, phase 3 trial of pembrolizumab plus epacadostat versus sunitinib or pazopanib as first-line treatment for metastatic renal cell carcinoma (KEYNOTE-679/ECHO-302) by Lara, Jr, Primo N, Villanueva, Luis, Ibanez, Carolina, Erman, Mustafa, Lee, Jae Lyun, Heinrich, Daniel, Lipatov, Oleg Nikolaevich, Gedye, Craig, Gokmen, Erhan, Acevedo, Alejandro, Semenov, Andrey, Park, Se Hoon, Gafanov, Rustem Airatovich, Kose, Fatih, Jones, Mark, Du, Xiaoqi, Munteanu, Mihaela, Perini, Rodolfo, Choueiri, Toni K, Motzer, Robert J

“…Immunotherapy-based combinations have emerged as standard therapies for patients with metastatic renal cell carcinoma (mRCC). Pembrolizumab, a PD-1 inhibitor,…”
Get full text

What is the predictive value of preoperative CA 125 level on the survival rate of type 1 endometrial cancer? by YILMAZ BARAN, Şafak, ALEMDAROĞLU, Songül, DOĞAN DURDAĞ, Gülşen, YÜKSEL ŞİMŞEK, Seda, AKA BOLAT, Filiz, KÖSE, Fatih, ÇELİK, Hüsnü

Get full text

Patient preferences for use of archived biospecimens in Turkey by Kubilay Tolunay, Pinar, Erol, Cihan, Kahraman, Seda, Tacar, Seher Yildiz, Özcan, Erkan, Basal, Fatma Bugdayci, Köse, Fatih, Sendur, Mehmet A.N., Tural, Deniz, Cicin, Irfan, Oksuzoglu, Berna, Ürün, Yüksel

“…e18904 Background: In the era of precision medicine translational research biospecimen collection and data sharing is increasingly needed. Ethical challenges…”
Get full text

Awareness and perceptions of clinical trials in patients with cancer and their families in Turkey by Kubilay, Pinar, Erol, Cihan, Kahraman, Seda, Tacar, Seher Yildiz, Özcan, Erkan, Basal, Fatma Bugdayci, Köse, Fatih, Sendur, Mehmet Ali Nahit, Tural, Deniz, Cicin, Irfan, Oksuzoglu, Berna, Ürün, Yüksel

“…e18780 Background: Patient preference plays an important role in enrolling in clinical trials. We conducted this study to understand the perceptions knowledge…”
Get full text

Atypical sweet syndrome in the hands of small cell lung cancer patient associated with granulocyte colony-stimulating factor administration by Ozlem, Dogan, Sedef, Ali Murat, Kose, Fatih, Ozyilkan, Ozgur

“…Sweet syndrome (SS) characterized by papules, plaques or nodules. SS was divided into three subcategories as classical SS, malignancy associated SS, and…”
Get full text

Addition of taxanes to combination chemotherapy in distal intestinal gastric cancer is more beneficial than proximal ones: A multicenter retrospective study of Turkish Oncology Group by Murat Sedef, Ali, Taner Sumbul, Fatih Kose Ahmet, Ayberk Besen, Ali, Hacioglu, Bekir, Gunaldi, Meral, Nayir, Erdinc, Tanriverdi, Ozgur, Arpaci, Erkan, Abali, Huseyin, Ozyilkan, Ozgur

“…Advanced gastric cancer has a dismal prognosis. Platin/5-fluorouracil (PF) combination chemotherapy is the main treatment modality for metastatic gastric…”
Get more information

Pembrolizumab (pembro) plus lenvatinib (lenva) in patients (pts) with docetaxel-pretreated, metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 cohort E by Augustin, Marinela, Laguerre, Brigitte, Baldini, Capucine, Zedan, Ahmed H., Gonzalez-Billalabeitia, Enrique, Fong, Peter C.C., Zukov, Ruslan, Hammerer, Peter, Prentice, Mark, Shore, Neal D., Necchi, Andrea, Todenhöfer, Tilman, Kessler, Elizabeth R., Köse, Fatih, Gurney, Howard, Perez Valderrama, Begona, Zhu, Pengfei, Imai, Kentaro, liu, yingjie, McDermott, Raymond S.

“…148 Background: More efficacious treatment options are needed to extend survival and disease control for pts with mCRPC whose disease progressed after…”
Get full text

Trial in progress update on ENGOT-cx8/GOG-3024/innovaTV 205: Addition of a new cohort with first-line (1L) tisotumab vedotin (TV) + pembrolizumab (pembro) + carboplatin (carbo) ± bevacizumab (bev) in recurrent/metastatic cervical cancer (r/mCC) by Vergote, Ignace, Mirza, Mansoor Raza, Sehouli, Jalid, Lorusso, Domenica, Köse, Fatih, Cibula, David, Westermann, Anneke M., Collins, Dearbhaile Catherine, Banerjee, Susana N., Oaknin, Ana, Soumaoro, Ibrahima, Jain, Shweta, Monk, Bradley J.

“…TPS5603 Background: Despite the use of platinum-taxane doublets ± bev in eligible patients (pts), overall survival (OS) outcomes for pts with r/mCC remain…”
Get full text

Türkiye'de Eğitim Yönetimi Alanındaki Yüksek Lisans Programlarının Okul Liderliği Standartları Çerçevesinde Değerlendirilmesi by Özdemir, Servet, Köse, Mehmet Fatih, Kavgacı, Hasan

“…Özet: Bu çalışmanın amacı, Türkiye’deki eğitim yöneticisi yetiştirmeye dönük lisansüstü bir program olarak kabul edilen Eğitim Yönetimi ve Denetimi (EYD)…”
Get full text

İstanbul’da tekke olarak kullanılan Roma ve Bizans kilise yapıları by Köse,Fatih

“…Bu makalede kronolojik olarak İstanbul’daki kilise yapılarında kurulan tekkeler hakkında bilgi verilecektir. 1453’te İstanbul’un fethinden sonra II. Mehmed…”
Get full text

Concurrent chemoradiotherapy with vinorelbine plus split-dose cisplatin may be an option in inoperable stage III non-small cell lung cancer: a single-center experience by Mertsoylu, Hüseyin, Köse, Fatih, Sümbül, Ahmet Taner, Sedef, Ali Murat, Doğan, Özlem, Besen, Ali Ayberk, Parlak, Cem, Fındıkçıoğlu, Alper, Muallaoğlu, Sadık, Sezer, Ahmet, Sakallı, Hakan, Özyılkan, Özgür

“…Concurrent chemoradiotherapy is the current standard treatment for inoperable stage III non-small cell lung cancer (NSCLC). In this study we aimed to…”
Get full text

ENGOT-ov65/KEYNOTE-B96: Phase 3, randomized, double-blind study of pembrolizumab versus placebo plus paclitaxel with optional bevacizumab for platinum-resistant recurrent ovarian cancer by Colombo, Nicoletta, Coleman, Robert L., Wu, Xiaohua, Köse, Fatih, Wenham, Robert Michael, Sebastianelli, Alexandra, Hasegawa, Kosei, Zsiros, Emese, De La Motte Rouge, Thibault, Bidziński, Mariusz, McNeish, Iain A., Sehouli, Jalid, Korach, Jacob, Debruyne, Philip R., Kim, Jae-Weon, de Melo, Andréia C., Peng, Xuan, Bogusz, Agata M., Yamada, Karin Sayuri, Monk, Bradley J.

“…TPS5617 Background: Despite therapeutic advances in ovarian cancer, platinum-resistant recurrent ovarian cancer (PROC) remains an area of high unmet clinical…”
Get full text

Neutrophil-to-lymphocyte ratio predicts PSA response, but not outcomes in patients with castration-resistant prostate cancer treated with docetaxel by Sümbül, Ahmet Taner, Sezer, Ahmet, Abalı, Hüseyin, Köse, Fatih, Gültepe, İlhami, Mertsoylu, Hüseyin, Muallaoğlu, Sadık, Özyılkan, Özgür

“…Purpose The neutrophil-to-lymphocyte ratio (NLR) is a marker of systemic inflammatory response and evidences for the relationship between NLR and the response…”
Get full text

Promising efficacy of sorafenib in a relapsed thymic carcinoma with C-KIT exon 11 deletion mutation by Dişel, Umut, Öztuzcu, Serdar, Beşen, Ali Ayberk, Karadeniz, Cemile, Köse, Fatih, Sümbül, Ahmet Taner, Sezer, Ahmet, Nursal, Gül Nihal, Abalı, Hüseyin, Özyılkan, Özgür

“…Abstract Advanced thymic carcinoma (TC) is a very aggressive disease. To date there are no established treatment options for the refractory and recurrent…”
Get full text